Data regarding overdoses of melphalan flufenamide are not readily available.L32173 However, nonclinical safety studies in dogs have shown an increased risk of mortality in subjects receiving higher than recommended doses.L32173 Patients should be treated with symptomatic and supportive measures.
Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan.A230123,L32173 Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases.A230123 In vitro models show that melphalan is 10 to hundreds of times more potent than melphalan.A230123 The increased potency makes melphalan flufenamide a treatment option for patients with relapsed or refractory multiple myeloma who have attempted at least 4 lines of therapy already.A230143,L32173
Melphalan flufenamide was granted FDA approval on 26 February 2021.L32173. It has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with pomalidomide and dexamethasone despite superior progression-free survival.L39085, L39090
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.